MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS
OBJECTIVE: Tumor related epilepsy (TRE) is an important complication in the treatment of brain tumors. In recent studies, it is assumed that isocitrate dehydrogenase (IDH) mutations are concerned with TRE in gliomas. Here, we examined the association between IDH mutations and TRE in our cases. METHO...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213400/ http://dx.doi.org/10.1093/noajnl/vdz039.102 |
_version_ | 1783531795511246848 |
---|---|
author | Wakabayashi, Hikaru Inaji, Motoki Fujii, Shoko Aoyama, Jiro Hashimoto, Satoka Tamura, Kaoru Maehara, Taketoshi |
author_facet | Wakabayashi, Hikaru Inaji, Motoki Fujii, Shoko Aoyama, Jiro Hashimoto, Satoka Tamura, Kaoru Maehara, Taketoshi |
author_sort | Wakabayashi, Hikaru |
collection | PubMed |
description | OBJECTIVE: Tumor related epilepsy (TRE) is an important complication in the treatment of brain tumors. In recent studies, it is assumed that isocitrate dehydrogenase (IDH) mutations are concerned with TRE in gliomas. Here, we examined the association between IDH mutations and TRE in our cases. METHODS: 115 patients who had a supratentorial glioma and were treated in our hospital from February 2009 to November 2018 were retrospectively assessed for IDH mutations and TRE. RESULTS: 38 patients were the IDH mutant group (16 females, mean age 43.7±12.9 years, mean follow-up time 44.0 months). 77 patients were the IDH wild group (35 females, mean age 61.6±16.6 year, mean follow-up time 18.1 months). Compared to the IDH wild group, the IDH mutant group was significantly younger and mean follow-up time was longer. There was no difference in the postoperative radiation and chemotherapy in both groups. The incidence of seizures as presenting symptom was 20 patients (52.6%) in the IDH mutant group and 16 patients (20.8%) in the IDH wild group, and was significantly higher in the IDH mutant group (p<0.01). 27 patients (71.1%) in the IDH mutant group had TRE at least once during follow-up time and 39 patients (50.0%) in the IDH wild group (p=0.06). In addition, the median OS for the group with seizure onset (36 patients) was 69.2 months and the group with the other onset forms (79 patients) was 22.4 months. The seizure onset group had a significantly better prognosis (p<0.05). CONCLUSION: Gliomas with IDH mutations have a higher incidence of TRE. Although IDH mutations are considered to be a risk factor for TRE, which is consistent with previous studies, but it is suggested that differences in survival may have an effect on the incidence of TRE. |
format | Online Article Text |
id | pubmed-7213400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72134002020-07-07 MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS Wakabayashi, Hikaru Inaji, Motoki Fujii, Shoko Aoyama, Jiro Hashimoto, Satoka Tamura, Kaoru Maehara, Taketoshi Neurooncol Adv Abstracts OBJECTIVE: Tumor related epilepsy (TRE) is an important complication in the treatment of brain tumors. In recent studies, it is assumed that isocitrate dehydrogenase (IDH) mutations are concerned with TRE in gliomas. Here, we examined the association between IDH mutations and TRE in our cases. METHODS: 115 patients who had a supratentorial glioma and were treated in our hospital from February 2009 to November 2018 were retrospectively assessed for IDH mutations and TRE. RESULTS: 38 patients were the IDH mutant group (16 females, mean age 43.7±12.9 years, mean follow-up time 44.0 months). 77 patients were the IDH wild group (35 females, mean age 61.6±16.6 year, mean follow-up time 18.1 months). Compared to the IDH wild group, the IDH mutant group was significantly younger and mean follow-up time was longer. There was no difference in the postoperative radiation and chemotherapy in both groups. The incidence of seizures as presenting symptom was 20 patients (52.6%) in the IDH mutant group and 16 patients (20.8%) in the IDH wild group, and was significantly higher in the IDH mutant group (p<0.01). 27 patients (71.1%) in the IDH mutant group had TRE at least once during follow-up time and 39 patients (50.0%) in the IDH wild group (p=0.06). In addition, the median OS for the group with seizure onset (36 patients) was 69.2 months and the group with the other onset forms (79 patients) was 22.4 months. The seizure onset group had a significantly better prognosis (p<0.05). CONCLUSION: Gliomas with IDH mutations have a higher incidence of TRE. Although IDH mutations are considered to be a risk factor for TRE, which is consistent with previous studies, but it is suggested that differences in survival may have an effect on the incidence of TRE. Oxford University Press 2019-12-16 /pmc/articles/PMC7213400/ http://dx.doi.org/10.1093/noajnl/vdz039.102 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Wakabayashi, Hikaru Inaji, Motoki Fujii, Shoko Aoyama, Jiro Hashimoto, Satoka Tamura, Kaoru Maehara, Taketoshi MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title | MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title_full | MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title_fullStr | MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title_full_unstemmed | MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title_short | MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS |
title_sort | mpc-05 tumor related epilepsy and idh mutations in gliomas |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213400/ http://dx.doi.org/10.1093/noajnl/vdz039.102 |
work_keys_str_mv | AT wakabayashihikaru mpc05tumorrelatedepilepsyandidhmutationsingliomas AT inajimotoki mpc05tumorrelatedepilepsyandidhmutationsingliomas AT fujiishoko mpc05tumorrelatedepilepsyandidhmutationsingliomas AT aoyamajiro mpc05tumorrelatedepilepsyandidhmutationsingliomas AT hashimotosatoka mpc05tumorrelatedepilepsyandidhmutationsingliomas AT tamurakaoru mpc05tumorrelatedepilepsyandidhmutationsingliomas AT maeharataketoshi mpc05tumorrelatedepilepsyandidhmutationsingliomas |